Mutations of Wnt/β-catenin signaling pathway has essential roles in development and cancer. Although β-catenin and adenomatous polyposis coli (APC) gene mutations are well established and are known to drive tumorigenesis, discoveries of mutations in other components of the pathway lagged, which hinders the understanding of cancer mechanisms. Here we report that δ-catenin (gene designation: CTNND2), a primarily neural member of the β-catenin superfamily that promotes canonical Wnt/β-catenin/LEF-1-mediated transcription, displays exonic mutations in human prostate cancer and promotes cancer cell survival adaptation and metabolic reprogramming. When overexpressed in cells derived from prostate tumor xenografts, δ-catenin gene invariably gives rise to mutations, leading to sequence disruptions predicting functional alterations. Ectopic δ-catenin gene integrating into host chromosomes is locus nonselective. δ-Catenin mutations promote tumor development in mouse prostate with probasin promoter (ARR 2 PB)-driven, prostate-specific expression of Myc oncogene, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivation. Reprogramming energy utilization accompanies the downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving tumor type 2 pyruvate kinase expression. δ-Catenin mutations increase β-catenin translocation to the nucleus and hypoxia-inducible factor 1α (HIF-1α) expression. Therefore, introducing δ-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating β-catenin and HIF-1α signaling under glucose shortage to amplify its tumor-promoting potential.
INTRODUCTION
Mutations, such as that of β-catenin and adenomatous polyposis coli (APC) genes of the Wnt/wingless signaling pathway, have pivotal roles in human diseases including cancer. 1 Mutations contribute to genetic instability, a major underlying hallmark of cancer, which propels human tumor progression. 2 Such mutations in oncogene β-catenin and tumor suppressor APC endow cancer cells with the ability to outgrow or outlive their neighboring cells not affected by mutations. 1 However, the understanding of other genes in the Wnt/wingless pathway is less clear. Many genes and their proteins, upon modifications, can elicit opposing growthpromoting and -suppressive functions at different cancer stages. Yet, little is known as to how these processes are controlled at the genetic level.
δ-Catenin/NPRAP/Neurojungin (gene designation: CTNND2) is primarily a neuronal protein expressed in the brain. [3] [4] [5] However, this initially described neural-specific member of the β-catenin/ armadillo superfamily is commonly overexpressed in cancers of peripheral tissues, including prostate, esophageal, breast, lung and ovarian cancers. [6] [7] [8] [9] Although the mechanisms of δ-catenin regulation in neurologic disorders and cancer are beginning to emerge, studies show that δ-catenin promotes canonical Wnt/β-catenin/LEF-1-mediated transcription. 10 δ-Catenin gene locus (5p15.2) is highly susceptible for generating single-nucleotide polymorphism (SNP). Compelling recent evidences have linked CTNND2 single-nucleotide polymorphism or mutations to cancer, myopia, cortical cataract and Alzheimer's disease. 11, 12 Chromothripsis and focal copy number alterations in 5p12-5p15 also determine poor outcomes in malignant melanoma. 13 In cancer cells, δ-catenin can exert both pro-and anti-growth effects and is correlated with poor patient survival. 9, 14, 15 Although the mechanisms by which these paradoxical functions are controlled genetically and how they promote cancer pathogenesis have not been well established, δ-catenin is a potential cancer biomarker and could be an important target for therapeutic interventions.
Here we took the advantage of a serendipitous discovery of induced CTNND2 mutations in cells derived from prostate cancer xenografts, which lead to sequence disruptions predicting functional alterations. We further revealed a broad spectrum of exonic mutations in δ-catenin associated with human prostatic adenocarcinoma. We found that the integration of ectopic δ-catenin gene into the host chromosomes is not locus selective. δ-Catenin mutations promote ARR 2 PB-driven, Myc-induced mouse prostate tumor development, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivation. We found that reprogramming energy utilization accompanies the downregulation of glucose transporter-1 (Glut-1) and poly (ADPribose) polymerase cleavage (PARP), preserving pyruvate kinase, tumor type 2 (PKM 2 ), β-catenin translocation to the nucleus and increases in HIF-1α expression. We conclude that the introduction of CTNND2 gene variation is an important milestone in prostate cancer metabolic adaptation, with the potential of being a target element for prostate cancer treatment.
RESULTS
Ectopically expressed δ-catenin is invariably mutated in prostate cancer cells We overexpressed δ-catenin into CWR22-Rv1 cells derived from human primary prostatic tumor xenografts and PC-3 cells of prostate cancer bone metastasis. Stable cell lines were successfully established. However, to our surprise, the full-length δ-catenin gradually and invariably gave way to faster migrating variants, which eventually stabilized at~100 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) when cells were cultured with repeated interruption of medium replenishments ( Figure 1a ). We initially regarded this variant as being derived either from a truncated cDNA contamination or proteolysis owing to unfavorable culture conditions. However, mapping with antibodies against epitopes covering the entire protein length ruled out cDNA contamination as the cause because it would have represented a nonexistent cDNA. We then applied a panel of protease inhibitors to determine whether the presumptive proteolysis can be reduced or prevented. E64D, E64D plus leupeptin (which inhibits most peptidases) or N-acetylcysteine (NAC) as an antiautophage/oxidant agent 16 did not inhibit this variant (Figure 1b ). E-cadherin and p120 ctn , two adherens junction proteins that are colocalized with δ-catenin and are known to undergo proteolysis, 17, 18 were quite stable under the same culture condition (Figure 1c) . The phenomenon that fast migrating protein bands became dominant over time was also observed in PC-3 cells stably transfected with the full-length δ-catenin ectopically (Figure 1d) . Furthermore, once cell cultures with the variant were established, the truncated protein could be observed from cells lysed soon after replating. Therefore, protein degradation due to culture aging cannot be the major mechanism of generating this variant.
A closer examination of δ-catenin cDNA isolated from the stable cell lines that express the mixed full-length and truncated δ-catenin bands showed sequence variations. This surprising result prompted the hypothesis that δ-catenin gene may be genetically targeted by cancer cells. We then sequenced the entire δ-catenin cDNA stably expressed in CWR22-Rv1 cells. We discovered that the cells expressing mainly the truncated δ-catenin variant displayed frame-shifting mutations that lead to premature termination (Figure 1e ). Remarkably, the predicted mutant protein variants derived from some of these premature terminations (e.g. exon 16 in Figure 1e ) fell in the close range of the size of the fast migrating protein band on SDS gels. To demonstrate that the mutations in δ-catenin can indeed generate the fast migrating protein band, we performed a mutagenesis experiment. We generated the identical mutation as the naturally occurring frame-shifting mutation described in Figure 1e , and then transiently transfected it into CWR22-Rv1 and PC-3 cells. Western blot analysis confirmed that the fast migrating protein band was at the same size of the predicted molecular weight for the truncated protein as the mutation would cause (Supplementary Figure S1) . These findings highlighted the potential of malignant tumor environment in inducing genetic mutations in an overexpressed gene.
There are hot-spot mutation cluster regions in CTNND2 exons in human primary prostatic adenocarcinomas The above data prompted the question of whether the mutations are the consequences of δ-catenin overexpression in cultures in vitro or reflect an event that also occurs in human prostate cancer in vivo 6,7 where δ-catenin expression is increased. Therefore, we sequenced and analyzed the entire coding region of δ-catenin gene (exons Table S1 ). Little or no missense or frame-shifting mutations were found in four exonic DNAs from clinically disease-free normal specimens (Figures 2b-f , top panels). We also did not observe significant mutations at the amino terminus corresponding to exons 1-9 ( Figure 2a ). These data strongly suggested that human δ-catenin gene contains hotspot mutation cluster regions (MCRs) in prostate cancer.
Examination of Sanger cancer gene mutation database found similar trends of sequence variation in δ-catenin coding region in other cancer types (http://cancer.sanger.ac.uk/cosmic/). For example, hot-spot MCRs are located at exons 10-14 and 17-22 in cancers, including lung, prostate, pancreas, skin, intestine and upper gastrointestinal tract cancers, as well as leukemia (Figure 3a and Supplementary Figure S2 ). The F1172F (c.3516C>T) mutation in exon 22 in human skin cancer, whereas it is a same-sense mutation, is identical to that in prostate cancer. A number of mutations predicted significant impact, as they either lead to premature termination or potential alteration of protein functions (Figure 3b ). Searching for commonly mutated genes in cancer exerts significant impact on effective cancer diagnosis and therapeutic design. 19, 20 Our findings clearly support δ-catenin as one such somatically mutated gene in prostate cancer.
CTNND2 mutations are not locus-selective and promote prostate tumor development in ARR 2 PB-driven Myc-expressing transgenic mice We then cloned CWR22-Rv1 cells that expressed only the truncated δ-catenin variant ( Figure 4a ). As expected, full-length δ-catenin was distributed at the cell-cell junction ( Figure 4b , GFP: arrows, Rv/δ). 5, 10 However, the truncated δ-catenin was exclusively cytoplasmic (Figure 4b , GFP: arrowhead, Rv/M1) and did not colocalize with the cell-cell junction protein p120 ctn (Figure 4b, p120 ctn : arrows). 5 We also examined CWR22-Rv1 cells stably transfected with cDNAs with amino-terminal 280-amino-acidtruncated (ΔN) or carboxyl-terminal 207-amino-acid-truncated (ΔC) δ-catenin (Figure 4c ). Although the truncation was further toward the carboxyl terminus, ΔC also showed cytoplasmic localization as Rv/M1 (Figures 4b and c , compare Rv/M1 and ΔC).
It is widely known that ectopically transferred genes do not insert into a specific chromosome in host cells. 21 Fluorescence in situ hybridization (FISH) analysis showed that a biotin-tagged DNA probe specific to δ-catenin DNA sequence-labeled multiple host chromosomes in δ-catenin-transfected cells (Figure 4d , Rv/δ) but not in vector-transfected control cells (Figure 4d , Rv/C). These observations suggest that the generation of δ-catenin mutations was not relying upon its bona fide chromosomal locus of 5p15.2. Cancer cells must have developed the capacity to target an overexpressed δ-catenin gene by altering its DNA sequences genetically. 22 We found that while Rv/δ cells grew faster as reported previously, 14 Rv/M1 cells grew slower than either Rv/C or Rv/δ cells. Likewise, Rv/ΔC cells showed a similar cell death rate to Rv/C, whereas apoptosis of Rv/δ cells was reduced (Supplementary Figure S3) . These results suggest that carboxyl-terminal deletion of δ-catenin did not confer growth advantage under the normal culture condition in which the supplies of glucose and serum factors were abundant. However, when cultures grew until they reached beyond full confluency, Rv/M1 cells displayed increased cell numbers (Figure 5a ). The tumor-promoting effects of δ-catenin truncation can also be demonstrated in vivo. Mice with δ-catenin gene disrupted in exon 9 23 and Myc oncogene conditionally expressed in the prostate 24 showed increased tumor size and progression from prostatic intraepithelial neoplasia δ-Catenin mutations lead to survival adaptation under glucose deprivation and reprogram energy utilization Recent studies highlighted the ability of cancer cells to adapt to glucose-deprived conditions by introducing mutations, for example, in Ras-expressing tumor cells. 22 When grown in culture with high glucose, Rv/M1 and Rv/C cells had similar death indexes, whereas that of Rv/δ cells was reduced ( Figure 6a , high glucose). However, under glucose deprivation, the death index of Rv/M1 cells reduced precipitously, whereas that of Rv/C cells increased markedly ( Figure 6a , low glucose). Rv/M1 cells were visibly more resilient to glucose starvation than Rv/C cells (Figure 6b ). According to Warburg hypothesis, cancer cells require much less energy to survive than they do for growth under densely packed conditions. 25, 26 δ-Catenin mutations clearly empowered prostate cancer cells with an increase in such capabilities of survival under glucose deprivation.
Our previous study showed that Rv/δ cells increased the expression of hexokinase II, a key enzyme for phosphorylation of glucose in entering glycolysis, which is increased in prostate cancer. 14, 27 To determine how δ-catenin mutations may reprogram energy metabolism to promote survival under nutrientdeprived conditions, we examined the ability of transfected cells to use energy. Under the normal growth condition, Rv/δ and Rv/M1 cells showed an increased ratio of oxygen consumption rate (OCR) over glycolysis-mediated extracellular acidification rate (ECAR) when compared with Rv/C cells (Figure 6c , high glucose). However, under glucose deprivation, Rv/M1 cells displayed higher OCR/ECAR than that of either Rv/C or Rv/δ cells (Figure 6c , low glucose).
After the cultures were maintained with low glucose for a week, Rv/C cells suffered massive cell death (Figure 6b , low-glucose Rv/C). Correspondingly, the OCR of Rv/C cells did not respond to 2, 4-dinitrophenol (Figure 6d ), indicating their reliance on glucose for mitochondrial respiration. 28 Rv/δ cell death was moderate, whereas Rv/M1 cell death was minimal (Figure 6b , Figure S5) . Therefore, Rv/δ and Rv/M1 cells preserved mitochondrial respiration capability and can unleash its use under glucose starvation. Continuing with 2-DG treatment, which inhibits glycolysis, 28 Rv/C and Rv/δ cells increased their relative OCR levels, but Rv/M1 cells showed a sharp reduction in OCR. Corresponding to the very low cell death observed under the low-glucose condition, the deficient OCR response of Rv/M1 following 2-DG treatment suggests the potential adaptation mechanisms by which δ-catenin mutations promote cell survival (Figure 6b ). All cells responded to rotenone, which inhibits mitochondrial NADH dehydrogenase/complex I and, consequentially, blocks mitochondrial respiration.
Although the tumor-selective PKM 2 was reduced in Rv/C cells upon glucose deprivation for 1 week, PKM 2 expression remained strong in Rv/δ and Rv/M1 cells (Figure 7a and Supplementary Figure S6A ). The expression of mitochondrial complexes was not significantly changed in Rv/M1 compared with Rv/C and Rv/δ cells (Figure 7a ). However, compared with Rv/C and Rv/δ, Rv/M1 cells showed reduced expression of cleaved poly (ADP-ribose) polymerase, a critical enzyme in the DNA repair defect-initiated apoptosis (Figure 7b and Supplementary Figure S6B ). Bcl-2 expression was increased in Rv/δ and Rv/M1 cells when compared with Rv/C cells with or without glucose deprivation (Figure 7b and Supplementary Figure S6A ). Glucose transporter-1 (Glut-1) showed a distinct shift of protein migration pattern of Glut-1H and Glut-1L variants from high glucose to low glucose culturing condition (Figure 7b ). Both variants showed a reduced expression under glucose deprivation in Rv/M1 cells (Figure 7b) .
To determine whether the changes in cell growth and survival properties involved Wnt/β-catenin signaling, we found that with high glucose in the medium, β-catenin expression and translocation to the nucleus was increased in Rv/δ and Rv/M1 in comparison with that of Rv/C (Figure 7c and Supplementary Figure S6C ), but there were no meaningful differences in HIF-1α expression among Rv/C, Rv/δ and Rv/M1 cells (Figure 7c and Supplementary Figure S6D , glucose). However, there was a remarkable increase in both β-catenin and HIF-1α expression and translocation to the nucleus in Rv/M1 compared with Rv/C cells during glucose deprivation (Figure 7d and Supplementary Figure S6 , no glucose). These results are consistent with our previous studies, 14 but further support that the carboxyl terminus of δ-catenin is important for prostate cancer expansion under the normal growth condition. Eliminating these sequences reassigned energy utilization for survival over proliferation-required biomass production under nutrition deprivation. 26 
DISCUSSION
Our studies identified that δ-catenin (CTNND2) gene displays somatic mutations that are highly inducible when overexpressed, likely representing and predicting an important milestone in prostate cancer cell survival and metabolic adaptation during densely packed tumorigenesis.
The molecular mechanism of inducible mutagenesis of δ-catenin in prostate cancer is not clear at present. Our studies showed that the generation of truncated δ-catenin protein species is not due to protein degradation. We also showed that the ectopic δ-catenin gene integrating into host chromosomes is not locally adherent to its native gene locus at Chr5p15.2. It is possible that an increased expression of δ-catenin ignited a feedback reaction onto replicating chromosomes where ectopic δ-catenin cDNA was inserted, and a low-fidelity replication due to destabilized genome in δ-catenin-transfected cells allowed unconserved base pairing to proceed. These random hits toward the 3′-region of ectopic δ-catenin sequences were then followed by a functional selection to favor carboxyl-terminal truncation mutant cells while eliminating full-length δ-cateninexpressing cells from the prostate cancer cell populations.
δ-Catenin is at the cross-points of several signaling pathways that have critical roles in development and cancer. δ-Catenin interacts with classical cadherins at their juxtamembrane domain, an association motif shared with that for p120 ctn , which is another protein of the delta subfamily (p120 ctn :CTNND1) of β-catenin/ armadillo superfamily. 5, 10, 29 This interaction is critical for regulating E-cadherin stability and in the brain it involves the regulation by presenilin of Alzheimer's disease. 30, 31 Although the roles of β-catenin and its mutations in development and cancer by effecting Wnt/wingless signaling are well established, recent evidence placed δ-catenin in the same pathway. Indeed, δ-catenin promotes E-cadherin processing and activates β-catenin-mediated signaling in human prostate cancer. 10 δ-Catenin was shown as a new member of the glycogen synthase kinase-3 (GSK-3) signaling complex that promotes β-catenin turnover. 32 GSK-3 phosphorylates δ-catenin and negatively regulates its own stability via ubiquitination/proteosome-mediated proteolysis. 33 Besides the interaction of δ-catenin and p120 ctn with the canonical Wnt-GSK-3-β-catenin-LEF1 signaling pathway, non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor, which is also a downstream target of δ-catenin and p120 ctn . [34] [35] [36] Therefore, δ-catenin is intimately involved in Wnt signaling and promotes cancer cell growth and shows poor cancer patient survival when it is overexpressed. When released from cadherins, δ-catenin clearly interacts functionally with actin regulatory network proteins, notably with Rho family small GTPases. Overexpression of δ-catenin induces branched cellular processes, which is reminiscent of RhoA inhibition. 37 δ-Catenin overexpression decreased the binding between p190RhoGEF and RhoA, and significantly lowered the levels of GTP-RhoA. 38, 39 δ-Catenin mutant cells (Rv/M1) survived better than Rv/C cells under glucose deprivation, but the expression of well-established mitochondrial complexes was not significantly changed. These data indicated that the changes in mitochondrial respiration owing to an altered expression pattern of these complexes are less likely the mechanisms of enhanced survival of Rv/M1 cells. Seahorse XF24 metabolic analysis showed that Rv/M1 cells are sensitive to the treatment of 2-DG, an inhibitor of glycolysis. Although we do not yet understand the molecular mechanisms how the truncated δ-catenin leads to metabolic reprogramming, it is possible that carboxyl-terminal truncation reduced the ability of δ-catenin to inhibit small GTPase RhoA 38 and allowed cytokinesis to proceed. The removal of cytokinesis inhibition could result in reprogramming energy utilization in cell cycle progression and prevent cytokinesis checkpoint-initiated apoptosis.
In normal cells, we propose that the full-length δ-catenin displays overall tumor-suppressive function. This means that overexpressing δ-catenin ectopically in a normal cell type would either inhibit or slow cell proliferation. This notion is supported by our studies as well as others. 5, 15 In malignant cancers, δ-catenin expression increased cell growth, whereas knockdown of δ-catenin reduced cell growth. This conclusion is supported by our studies as well as others. 9, 14, 40 This is also true in the current study when prostate cancer cells grow under abundant serum and high-glucose condition. However, as the cancer cells deregulate many gene's expression during transformation, some genes, when their expressions being overly high, can be harmful for overall tumor growth if the nutrition supplies cannot match the demand of rapid growth in certain tumor areas. We hypothesize that the amino terminus of δ-catenin may promote cancer cell growth and survival, 14 whereas the carboxyl terminus of δ-catenin when overly active interacts with the small GTPase RhoA to inhibit cytokinesis as seen in p0071. 41 When the promoter of δ-catenin is activated in prostate cancer, 6 ,42 the cancer cells could balance the rate of cell cycle progression by sensing the nutrition supplies. When nutrition is abundant, δ-catenin amino-terminal function dominates and its carboxyl-terminal interaction with RhoA is limited. When nutrition is limited, cancer cells adapt to inactivate the overexpressed δ-catenin carboxyl terminus. This modulation may create a favorable situation for cancer cells to continue to grow and survive under the stressful condition of rapid overgrowth, but avoid its elimination owing to conflict between rapid cell cycle entrance and delayed cytokinesis.
In the case of Myc-driven prostate cancer mouse model, Myc overexpression promoted the proliferation and transformation. However, δ-catenin expression on promoting cell cycle entrance without proceeding through cytokinesis may not be favorable for tumorigenesis. In this case, the δ-catenin carboxyl-terminal truncation mutant may function to release this inhibition.
Recent studies of Rho GTPase links to mitochondrial enzyme glutaminase (GLS1) suggested that signaling via the Rho GTPases, together with nuclear factor-κB, can elevate mitochondrial glutaminase activity in cancer cells, thereby helping cancer cells meet their altered metabolic demands. 43 There is also evidence that TSC2 inhibits cell growth by acting as a GTPase-activating protein toward Rheb, thereby inhibiting mammalian target of rapamycin. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK-3 to regulate cell growth. 44 Despite the understanding of δ-catenin functions in Rho GTPase 38, 39, 45, 46 and Wnt/β-catenin signaling, 10, 32, 33 the current study is the first to provide significant evidence of exonic mutations in δ-catenin coding region and demonstrate their consequences in cancer metabolic adaptations in tumor progression.
These studies thus raise questions for cancer mechanisms and drug targeting strategies. Cancer cells can apparently alter genetic composition and subsequent functions of foreign DNAs, potentially evading ectopic expression-based gene therapy. In addition, targeting cancer metabolism may benefit by incorporating enforcers that inhibit genes promoting adaptation under metabolic stress. Finally, chromosomal machinery responsible for mutagenesis is likely not locally adhering to a specific gene locus and is deregulated in cancer homing for introduction of cancerdriving and -adapting mutations. We have now succeeded in generating innovative cell and mouse models that can potentially elucidate such mechanisms that can hold a key to reduce genomic rearrangements and make targeting cancer more effective.
MATERIALS AND METHODS

Antibodies and reagents
Mouse anti-E-cadherin, anti-p120 ctn and anti-δ-catenin clone 30 (to amino acids 85-194) were from BD Biosciences (Palo Alto, CA, USA). Monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase was from EMD Science (Darmstadt, Germany). Rabbit, guinea-pig and mouse antibodies against different epitopes of mouse or human δ-catenin (epitopes on mouse 85-194, 292-309, 691-708, 1017-1035; human 434-530, 828-1022) were described previously. 4, 5 Rabbit anti-poly (ADP-ribose) polymerase and anti-PKM 2 were from Cell Signaling Technology (Danvers, MA, USA). Rabbit anti-HIF-1α and anti-Bcl-2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), whereas rabbit anti-β-catenin was from Sigma (St Louis, MO, USA). Rabbit anti-Glut-1 and mouse anti-mitochondrial NADPH dehydrogenase/ complex cocktail were from Abcam (Cambridge, MA, USA). All other chemicals were from Sigma, unless indicated otherwise.
Cell culture, mutagenesis and transfection Human prostate tumor xenograft CWR22-Rv1 or PC-3 cells were stably transfected with full-length δ-catenin (named as Rv/δ) or GFP vector alone (named as Rv/C) using FuGENE 6 (Roche Scientific, Gaithersburg, MD, USA). For selection of pEGFP-δ-catenin-transfected cells, cells were first selected in G418-containing medium. Then, pEGFP-δ-catenin-transfected cells were further selected by GFP-based cell sorting using a FACS Vantage (BD Biosciences). The amino-terminal 280-amino-acid-deleted (Rv/ΔN) or carboxyl-terminal 207-amino-acid-deleted (Rv/ΔC) δ-catenin cDNA with pEGFP fusion were transfected similarly. The stable cell lines were maintained in RPMI1640 medium containing 25 mM glucose and supplemented with 10% fetal bovine serum (FBS) and 0.25% gentamicin (G418) (Gibco, Grand Island, NY, USA). To generate spontaneously truncation variants, cell cultures were plated in high-glucose medium with 10% FBS, followed by repeated interruption of medium replenishment. Cells subjected to glucose deprivation were cultured in RPMI1640 medium with 0.25 mM or no glucose and supplemented with 10% dialyzed FBS. All cells were incubated at 37°C in 5% CO 2 environment.
To generate the truncated δ-catenin with targeted mutation, we performed in vitro mutagenesis with the following strategy. We took a part of δ-catenin sequence from the original pEGFP-δ-catenin vector and made the mutation to 5′-TGGGCTGAGGAATGTGGCAGGC-3′ from 5′-TGG GCTGAGGATGTGGCAGGC-3′ using primer sets as forward primer 5′-AAG GGCTGGGCTGAGGAATGTGGCAGGCATGG-3′ and reverse primer 5′-CCATG CCTGCCACATTCCTCAGCCCAGCCCTT-3′ by polymerase chain reaction (PCR). This mutation predicts a stop codon after 138-nucleotide sequence in the mutant δ-catenin. Mutated δ-catenin sequence was verified by sequencing.
Genomic DNA extraction from tissue and PCR amplification of δ-catenin gene
The archival paraffin blocks of radical prostatectomy cases were performed at the Brody School of Medicine (Greenville, NC, USA). The clinical pathology analysis regarding Gleason score, tumor stage and status of surgical margins were assessed as described. 7 All 16 prostate cancer and clinically disease-free tissue samples were transferred to the laboratory according to the Institutional Research Board-approved protocol no. 06-0300. In addition, two cases of commercial DNA from prostate cancer patients were obtained from Promega (Madison, WI, USA).
Genomic DNAs were extracted from fresh tissue using DNeasy Tissue Kit (Qiagen Science, Germantown, MD, USA) or from paraffin-embedded primary prostatic adenocarcinoma samples and non-cancer prostate tissues.
PCR analysis was performed to amplify δ-catenin exon sequences using genomic DNA as templates from cells of prostate cancer tissue specimens. The PCR primers and reaction conditions used for detection of δ-catenin DNA sequences were listed as seen in Supplementary Materials and methods.
PCR products sequence analysis
The purified PCR products using QIAquick PCR Purification Kit (Qiagen Science) were sent for sequencing. The DNA sequences of amplified PCR fragments obtained from prostate cancer tissues were compared with human δ-catenin DNA sequence as reference published in the NCBI database using BLAST Program.
To conduct MCR analysis, mutations deposited in the Sanger cancer sequencing database were combined with the ones in this study. Nucleotide position of the mutations was plotted against the exons in δ-catenin.
Genomic DNA extraction from cultured cell line and PCR amplification of mouse δ-catenin cDNA sequence PCR analysis was performed to amplify δ-catenin exon sequence using genomic DNA as templates isolated from Rv/δ and Rv/C cell lines. The PCR primers and reaction conditions used for detection of mouse δ-catenin cDNA sequences were listed as seen in the Supplementary Materials and methods.
Purified PCR products were sequenced and compared with mouse δ-catenin cDNA sequence as reference published in the NCBI database using BLAST Program. , we designated it as No Myc/δ − / − in this study) was described earlier. 23 This mutant showed expression of δ-catenin with the intact amino-terminal 435 amino acids after a targeted disruption of exon 9. The Myc transgenic mice (ARR 2 PBMyc) showed tissue-specific expression of Myc in the mouse prostate, which was described previously. 24 The animals were kept under pathogenfree conditions according to the guidelines of East Carolina University Animal Use Protocol. These two mouse strains were cross-bred, and the offsprings were aged to determine if prostate lesion developed in the transgene-positive mice.
The genotypes were confirmed by collecting DNA from tail snips at 3 weeks after birth. Mouse-tail DNA was subjected to a PCR-based screening assay for genotyping. For Myc transgenic mouse genotype (ARR 2 PB-Myc), primers were selected as follows: MO45 (5′-AAACATGATGAC TACCAAGCTTGGC-3′) is specific for the ARR 2 PB promoter element, and MO47 (5′-ATGATAGCATCTTGTTCTTAGTCTTTTTCTTAATAGGG-3′) is specific for the noncoding region upstream to the probasin promoter, which resulted in a PCR product of 100-200 bp. For δ-catenin mutants (No Myc/δ-cat − / − ), two different sets of primers were used as follows: primers for WT (No Myc/δ-cat +/+ ) include F1 (5′-GACGTTTGGTTTTCCGAATG-3′) and R3 (5′-AGAGTCAACGGAGGCACAAT-3′), and primers for δ-catenin mutants (No Myc/δ-cat À / À ) include exon 9 forward (5′-AACCGTTTCTGTGAGCAGG TCC-3′) and GFP1300 reverse (5′-GCTCGTCCATGCCGAGAGTG-3′), resulting in PCR product 2000 and 800 bp, respectively.
For histological examination, mice were killed at 6 months. The prostate tissues were dissected, fixed in 4% paraformaldehyde and stored at 4°C. Serial tissue sections (5 μm thick) were cut from paraffin-embedded blocks and placed on charged glass slides. Hematoxylin and eosin staining was performed using standard procedures. All slides were analyzed by light microscopy using a Carl Zeiss microscope equipped with Axiovision Rel 4.8 imaging software (Carl Zeiss, Thornwood, NY, USA).
Immunofluorescent light microscopy
Cultured cells were plated on the coverslips and fixed in warm 4% paraformaldehyde. Following permeabilization in 0.2% Triton X-100, the cells were stained using mouse monoclonal anti-p120 ctn . The cells were then incubated with the goat anti-mouse Cy3 conjugated secondary antibodies. The nuclei of the cells were stained with Hoechst 33258. The coverslips were mounted on slides using antifade medium (Invitrogen, Carlsbad, CA, USA) and photographed under the Zeiss Axiovert inverted fluorescent microscope (Carl Zeiss).
To detect cell proliferation and apoptosis, frozen mouse prostate sections were immunostained using anti-Ki67, a marker of cell proliferation and TUNEL assay, which detects cells undergoing apoptosis. Hoechst, a marker for nuclei, was used to stain all cells. Immunofluorescent density analyses were performed using a MetaMorph 4.6 imaging software system (Universal Imaging Corp., West Chester, PA, USA). All data were presented as mean ± s.e.m. and statistically evaluated with a t-test. The confidence level was set at 0.05.
Western blot with ECL detection
Cells for protein analysis were lysed in RIPA buffer (1% Triton X-100, 0.5% deoxycholic acid, 0.2% SDS, 150 mM sodium chloride, 2 mM EDTA) with complete protease inhibitor cocktail tablet (Roche, Mannheim, Germany) and pepstatin A. After removing cell debris by centrifugation, protein concentration was determined using the bicinchoninic acid method. The proteins separated by SDS-PAGE were transferred to the nitrocellulose membrane (Optitran by Whatman GmbH, Dassel, Germany) for western blot analyses. After incubation in appropriate primary and secondary antibodies, the membranes were developed with ECL detection reagents (GE Healthcare, Buckinghamshire, UK). Densitometry using Quantity One (Bio-Rad, Hercules, CA, USA) was carried out to measure semiquantitatively protein intensity on the western blot analysis. Statistical analysis was performed to obtain means and s.e.m.'s with P-values.
Chromosome spread preparation
Metaphase chromosomes were prepared following the method of Deng et al., 47 with minor modification. Briefly, the cells were treated with nocodazole (0.01%) at 37°C for 3 h. After treating with hypotonic solution (0.8% sodium citrate), the cells were prefixed in freshly prepared Carnoy's fixative (methanol:glacial acetic acid = 3:1 (v/v)) for 10 min. The cells were collected by centrifugation and washed with Carnoy's fixative three times. After the final centrifugation, the supernatant was removed completely and the cell pellet was resuspended in 0.3 ml of Carnoy's fixative, and the optimal cell spreading was accomplished.
Fluorescence in situ hybridization
To determine whether mouse δ-catenin cDNA integrates into multiple chromosomes after transfection and stabilization into cultured CWR22-Rv1 cells, biotin-labeled probe were designed for FISH analysis. The probe for oligonucleotide sequences was as follows and labeled with biotin at the 5′ terminus: TCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTATGTTC GCCAGGAAGCAGTCGG.
FISH was carried out according to Huang et al., 48 with some modifications. Briefly, the chromosomes spreads were digested at 37°C with 0.01% prewarmed pepsin in 10 mM HCl for 10 min. After prefixing with 37% formaldehyde for 5 min at room temperature, the chromosome spreads were denatured in a mixture containing 75% formamide and 2 × saline-sodium citrate (SSC) at 75°C for 15 min, dehydrated with a chilled ethanol series, 70%, 90%, 100%, respectively, for 3 min each and air-dried. The hybridization mixture (10 ng/μl probes, 10% dextran sulfate and 50% deionized formamide in 2×SSC) was denatured at 100°C for 15 min and chilled immediately by being put on ice for at least 5 min. Denatured probe was applied onto the slide and DNA-DNA in situ hybridization was carried out in a humidity chamber at 37°C overnight. Following hybridization, the slides were washed in 2 × SSC at 37°C for 10 min, 0.2 × SSC at 53°C for 5 min and, finally, briefly equilibrated with 4x SSC/Tween-20 at room temperature. The slides were then blocked with 3% bovine serum albumin in 4x SSC/Tween-20 solution at 37°C for 30 min. After washing with 4x SSC/Tween-20 at 45°C for 5 min, the slides were incubated with anti-avidin-Cy3 (1:500 dilution in 4x SSC, 0.1% Tween-20, 1% bovine serum albumin) at 37°C for 30 min. Finally, chromosomes were counterstained with Hoechst and mounted with antifade medium before imaging acquisition and analysis under Zeiss Axiovert fluorescence light microscope equipped with the MetaMorph software (Carl Zeiss).
Cell growth with high glucose or with glucose deprivation Cells under the normal growth condition with high glucose and FBS for 7 days were harvested after trypsinization and mixed with trypan blue at a 1:1 dilution. They were counted using an automated cell counter (Invitrogen; Countess). All experiments were performed in triplicate. Data are expressed as mean ± s.e.m. To determine growth after cells piled up, cells were plated in the FBS-containing medium for 2 days and were replenished with fresh FBS, allowing them to grow to near confluency. Then, the cell numbers were counted following an additional 5 days without fresh FBS replenishment.
Some cell cultures grown under high glucose (25 mM) or low glucose (0.25 mM) with dialyzed FBS were divided into two groups: healthy adherent cells and detached dying cells. The ratio of detached to adherent cells was designated as the death index.
To determine cell death by flow cytometry, Rv/C, Rv/δ, Rv/ΔN and Rv/ΔC cells were grown to 60% confluency, trypsinized and centrifuged at 1000 r.p.m. to pellet the cells. The supernatant was carefully removed and the cells were resuspended in 0.7 ml cold 100% ethanol and 0.3 ml cold phosphate-buffered saline. The cells were stained with propidium iodide before they were taken for flow cytometry analysis. The propidium iodide staining solution was made with 470 μl phosphate-buffered saline with 5 μl RNase A and 25 μl stain propidium iodide (1 mg/ml in deionized water). The cells were incubated in propidium iodide stain for 1 h. The cell counts were obtained using the CellQuest software (BD Bioscience, San Jose, CA, USA), with the parameters set to include apoptosis as sub-G1 populations. The data were analyzed by taking the mean and s.e.m. results.
Metabolic measurement
Two days before the experimental analysis, Rv/C, Rv/δ and Rv/M1 cells were plated (20 000 cells per well) onto custom XF24 microplate (Searhorse Bioscience, North Billerica, MA, USA). Some cells were cultured in the presence of normal glucose (25 mM) and 10% FBS, whereas other cells were cultured in low glucose (0.25 mM) with dialyzed FBS. Cells were rinsed three times in unbuffered Dulbecco's modified Eagle's medium, and incubated for 1 h at 37°C without CO 2 in 600 μl of unbuffered Dulbecco's modified Eagle's medium (pH 7.4) supplemented with 10 mM glucose and 1 mM sodium pyruvate. The cell glycolysis (ECR) and mitochondrial oxidative phosphorylation (OXPHOS) (OCR) were measured in real-time using a Seahorse Bioscience XF24 Extracellular Flux Analyzer Induced δ-catenin functional mutations J Nopparat et al (Seahorse Bioscience, Billerica, MA, USA). Following the basal rates of OCR and ECAR measurements, a series of injections of three compounds that affect bioenergetics was introduced, which included: 100 μM 2, 4-dinitrophenol, 100 mM 2-deoxyglucose and 1μM rotenone. Each cell type was plated and analyzed by quintuplicate while outliers were removed so the most consistent triplicate data were integrated.
Preparation of nuclear and cytoplasmic protein fractions
To prepare the cytoplasmic and nuclear fractions, cultured Rv/C, Rv/δ and Rv/M cells were resuspended in buffer A containing 15 mM HEPES (pH 7.4), 80 mM KCl, 15 mM NaCl, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and 25 mM sucrose with protease and phosphatase inhibitor cocktails. The cells were lysed in the buffer, homogenized in a syringe with 22 G needles and centrifuged at 1000 r.p.m. for 10 min at 4°C. The supernatants were again centrifuged at 21 000 r.p.m. (Beckman Coulter Optima Max-E ultracentrifuge, Beckman Coulter, Brea, CA, USA) for 90 min at 4°C. The supernatants were used as the cytoplasmic fractions, and the pellets were used as the nuclear fractions.
